The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients - impact of response or failure under anti-EGFR therapy

被引：0
|
作者：
Berger, A. W. [1 ]
Schwerdel, D. [1 ]
Welz, H. [1 ]
Moeller, P. [2 ]
Ettrich, T. J. [1 ]
Seufferlein, T. [1 ]
机构：
[1] Univ Ulm Klinikum, Klin Innere Med 1, Ulm, Germany
[2] Univ Ulm Klinikum, Inst Pathol, Ulm, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0514
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [1] The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients: Impact of response or failure under anti-EGFR therapy.
    Berger, Andreas W.
    Schwerdel, Daniel
    Welz, Hanna
    Ettrich, Thomas Jens
    Moeller, Peter
    Seufferlein, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
    Bouchahda, Mohamed
    Saffroy, Raphael
    Karaboue, Abdoulaye
    Hamelin, Jocelyne
    Innominato, Pasquale
    Saliba, Faouzi
    Levi, Francis
    Bosselut, Nelly
    Lemoine, Antoinette
    JCO PRECISION ONCOLOGY, 2020, 4 : 1070 - 1079
  • [3] New predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Masaki, Tadahiko
    Matsuoka, Hiroyoshi
    Kojima, Koichiro
    Asoh, Nobuyoshi
    Beniya, Ayumi
    Sakamoto, Yoshihiro
    Mori, Toshiyuki
    Abe, Nobutsugu
    CANCER SCIENCE, 2018, 109 : 1378 - 1378
  • [4] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Jose A. García-Sáenz
    Javier Sastre
    Eduardo Díaz-Rubio García
    Clinical and Translational Oncology, 2009, 11 : 737 - 747
  • [5] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Garcia-Saenz, Jose A.
    Sastre, Javier
    Diaz-Rubio Garcia, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 737 - 747
  • [6] Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer
    Perkins, Geraldine
    Pilati, Camilla
    Blons, Helene
    Laurent-Puig, Pierre
    PHARMACOGENOMICS, 2014, 15 (07) : 1043 - 1052
  • [7] PREDICTIVE MOLECULAR BIOMARKERS IN COLORECTAL CANCER: IS KRAS AND BRAF WILD TYPE STATUS REQUIRED FOR ANTI-EGFR THERAPY?
    Marchoudi, N.
    Joutei, H. Amrani Hassani
    Jouali, F.
    Fekkak, J.
    Rhaissi, H.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6048 - 6048
  • [8] Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
    Er, Tze-Kiong
    Chen, Chih-Chieh
    Bujanda, Luis
    Herreros-Villanueva, Marta
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [9] EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy
    Uhlyarik, A.
    Piurko, V
    Vizkeleti, L.
    Papai, Zs
    Raso, E.
    Lahm, E.
    Kiss, E.
    Sikter, M.
    Vachaja, J.
    Kenessey, I
    Timar, Jozsef
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1429 - 1434
  • [10] Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer
    Kucukoner, Mehmet
    Oztekin, Esen
    Akdeniz, Nadiye
    Morkuzu, Suat
    Yerlikaya, Halts
    Urakci, Zuhat
    Kaplan, Muhammed Ali
    Isikdogan, Abdurrahman
    JOURNAL OF BUON, 2019, 24 (04): : 1501 - 1506
12345